欣维宁对冠脉内急性血栓作用的临床研究

Clinical study of the effection of Tirofiban on acute thrombus forming in coronary artery

目的观察欣维宁在经皮冠状动脉介入治疗时对急性血栓的作用及与其他抗栓药物联合运用的安全性。方法将23例介入治疗后发生急性血栓的急性冠脉综合征患者随机分成3组,分别给予欣维宁静滴(治疗组,11例)、欣维宁+尿激酶静滴(联合组,6例)、尿激酶静滴或置入支架(对照组,6例)。结果 3组的心血管不良事件发生率分别为9.9%,16.7%,66.7%;CK-MB峰值分别为(374.±2229.3)U/L、(295.9±325.4)U/L、(693.7±238.7)U/L;CK-MB达峰和持续时间分别为(21.0±6.3)h、(63.3±18.8)h,(21.0±4.2)h、(53.0±4.2)h,(41.2±3.6)h、(101.8±6.3)h.结论治疗组、联合组在血流恢复、心肌酶谱改变等方面优于对照组,2组间差异不明显,但联合组出血并发症增多。

Objective To evaluate the effection of tirofiban on acute thrombus forming in percutaneous coronary intervention and the safety combined with other antiplatelet anticoagulation drugs.Methods 23 patients with acute thrombus during PCI were divided into 3 groups randomly.11 cases were treated with Tirofiban only,6 patients received the treatment with urokinase intravenously guttae or implanted a second stenting,the other 6 patients were treated with tirofiban plus urokinase.Results The ratio of MACE（the 7th day） of Tirofiban group,combined group and control group were 9.9%,16.7% and 66.7%.The peak value of CK-MB in 3group were（374.2±229.3）U/L,（295.9±325.4）U/L and（693.7±238.7）U/L respectively.The reaching-peak and lasting time of CK-MB of these 3 group were（21±6.3）h,（63.3±18.8）h,（21±4.2）h,（53±4.2）h,（41.2±3.6）h and（101.8±6.3）h.Conclusion Zymogram change and blood flow recover in treatment group and unite group is better than that in control group.There is no significant differences between these two groups.But the combination group has more complications of bleeding.